A Study to Evaluate Circulating Tumor Cells from Patients with Treatment-Refractory Advanced Solid Tumors Managed in the Early Cancer Therapeutics Program

Overview

About this study

The overall objective of this research is to evaluate and define the molecular and biological characteristics of CTCs from advanced solid tumor patients who have progressed on standard therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Has advanced, non-curable solid tumor for which no standard curative or life prolonging therapy is available
  2. Patients who are candidate for management at Early Cancer Therapeutics Clinic will be eligible

Exclusion Criteria: 

  1. Presence of another active cancer(s) diagnosis within the past 2 years except for definitively treated localized basal cell and squamous cell carcinoma of the skin

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Wen Wee Ma, M.B.B.S.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20312022

Mayo Clinic Footer